$BCRX

Otsuka's sibeprenlimab showed eGFR stabilization in IgA nephropathy. FDA approved BioCryst's berotralstat pellets, AstraZeneca's ravulizumab for IgA nephropathy, AbbVie's risankizumab for Crohn's, and GSK's bepirovirsen for hepatitis B. Key data: sibeprenlimab +0.3 vs. placebo -4.2 mL/min/1.73 m²/year; ravulizumab reduced UPCR by 43.4%; risankizumab 56% remission vs. 30% placebo; bepirovirsen 19% functional cure rate.

BioCryst Pharmaceuticals announced FDA approval of a 150 mg oral pellet formulation of berotralstat (Orladeyo) for HAE prophylaxis in patients aged 12+. The approval adds a second dosage form, following prior approvals for capsules and pediatric pellets. BioCryst reports berotralstat is the only targeted oral prophylactic therapy for HAE patients aged 2+.

BioCryst Pharmaceuticals (BCRX) reported Q2 2026 revenue of $218.3M, up 34% YoY, with Orladeyo contributing $158.2M. The company faces potential competition from Pharvaris' HAE treatment. Analysts have mixed views on BCRX's future, with RBC downgrading and Wedbush maintaining an Outperform rating. BCRX trades at 10.83x forward earnings, below the sector median.

BioCryst Pharmaceuticals (BCRX) formed a Scientific Advisory Board with seven experts in rare disease research. The board will guide the company's R&D strategy and pipeline development, focusing on external innovation. BioCryst has commercialized ORLADEYO and is advancing a pipeline of rare disease therapeutics.

Anthropic’s Claude AI sold positions in Ardelyx (ARDX) and Aris Mining (ARIS), buying Syndax Pharmaceuticals (SNDX) and BioCryst (BCRX). BioCryst's Orladeyo treats hereditary angioedema, with patent protection until 2040. Despite competition concerns, Claude sees potential in BioCryst's growth and hedging strategy. The company's earnings report in early November is a key focus.

BioCryst Pharmaceuticals (BCRX) received approval in Japan for its drug ORLADEYO to treat children aged 2-12 with hereditary angioedema, expanding its global reach. The company reported Q2 revenue of $218.3M, up 34% YoY, and $98.5M in operating profit. BCRX has a forward P/E of 14.86 and positive free cash flow, supporting its growth strategy.

BioCryst acquired Astria for ~$700M, aiming for $1B rare-disease market. Focus on ORLADEYO, with 60% patient retention. Plans for navenibart and BCX17725. Expects growth in HAE market, pediatric use, and normal C1 inhibitor patients. Maintains profitability.

BioCryst Pharmaceuticals (BCRX) reported its first profit, driven by sales of Orladeyo, and plans to acquire more rare disease treatments. CEO Charlie Gayer aims to grow profits annually without external capital. Orladeyo is projected to generate up to $645M in 2026 sales. The company recently acquired Astria Therapeutics, adding navenibart to its pipeline. BioCryst has $822M in debt and relies heavily on Orladeyo for growth.

BioCryst Pharmaceuticals (BCRX) shares fell 9% on Tuesday, their worst day in over 6 months, after competitor Pharvaris (PHVS) reported positive late-stage trial results for a rare swelling disorder treatment. PHVS shares rose 7% during trading and 3% after-hours. Orladeyo, BioCryst's approved treatment, generated over $2B in revenue since 2020 and is expected to bring in $625M-$645M this year. BioCryst is also developing a second treatment, navenibart, with late-stage data expected in 2027.

RBC Capital downgraded BioCryst Pharmaceuticals (BCRX) to 'Sector Perform' and cut its price target to $11, citing competition from Pharvaris's (PHVS) strong HAE therapy data. BCRX shares fell 8%, heading for a fifth straight day of losses. Orladeyo's revenue is expected to drop to $400M-$450M due to competition, though Navenibart's Phase 3 data is awaited in 2027.